Table 2.
Baseline demographic and clinical characteristics of patients with PM-CNV.
| Characteristics | Type 1 | Type 2 | P |
|---|---|---|---|
| No. of eyes, n | 20 | 28 | |
| Age, y, mean ± SD | 44.60 ± 11.89 | 44.64 ± 13.0 | 0.991a |
| Sex, n | |||
| Male | 5 | 11 | |
| Female | 15 | 17 | |
| BCVA at baseline (LogMAR), mean ± SD | 0.62 ± 0.214 | 1.132 ± 0.302 | <0.001 a |
| CNV area, (mm2), median (IQR) | 0.052 (0.034–0.088) | 0.343 (0.235–0.374) | <0.001 b |
| HRF height, (μm), median (IQR) | 0 (0–25) | 130 (87–200) | <0.001 b |
| Appearance of EZ | <0.001 c | ||
| Intact = 20 | Intact = 6 | ||
| Disrupted = 0 | Disrupted = 10 | ||
| Absent =0 | Absent = 12 | ||
| Appearance of RPE | <0.001 c | ||
| Intact = 20 | Intact = 0 | ||
| Disrupted = 0 | Disrupted = 18 | ||
| Absent =0 | Absent = 10 | ||
| Total number of anti-VEGF injections, median (IQR) | 2 (1–2) | 3.5 (2–4) | <0.001 b |
| Follow-up period (mo), median (IQR) | 6 (6–7) | 7 (6–8) | 0.081b |
| Recurrence of PM-CNV, n (%) | 10 (50%) | 22(78.57%) | <0.001 c |
| Time interval to recurrence (mo), median (IQR) | 2.5 (1.75–4) | 1 (1–2) | 0.031 b |
| Intraretinal or subretinal fluid, n (%) | 3 (15%) | 18 (64.29%) | < 0.001c |
PM, pathologic myopia; CNV, choroidal neovascularization; SD, standard deviation; BCVA, best corrected visual acuity; LogMAR, logarithm of the minimum angle of resolution; IQR, interquartile range; HRF, hyperreflective foci; EZ, ellipsoid zone; RPE, retinal pigment epithelium; P with statistical significance is shown in boldface; aUnpaired t-test; bMann - Whitney test; cFisher exact text.